| A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP) (NCT07761429) | Shandong New Time Pharmaceutical Co., LTD | 2026-07-08 |
| Phase I Clinical Study of LNF2105 in Patients With Advanced Solid Tumors (NCT07661797) | Shandong New Time Pharmaceutical Co., LTD | 2026-06-01 |
| A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma (NCT07579234) | Shandong New Time Pharmaceutical Co., LTD | 2026-01-25 |
| Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes (NCT07046273) | Shandong New Time Pharmaceutical Co., LTD | 2025-08-01 |
| A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma (NCT07312188) | Shandong New Time Pharmaceutical Co., LTD | 2025-07-02 |
| A Phase III Clinical Study of Valsartan Oral Solution for the Treatment of Hypertension in Children and Adolescents (NCT06863987) | Shandong New Time Pharmaceutical Co., LTD | 2025-02-05 |
| Phase II Clinical Study of Vonorasan Fumarate Injection in the Treatment of Peptic Ulcer Bleeding (NCT06783257) | Shandong New Time Pharmaceutical Co., LTD | 2025-02-01 |
| A Phase I Study OfLNF2007 Monotherapy in Patients with Advanced Solid Tumors (NCT06752447) | Shandong New Time Pharmaceutical Co., LTD | 2025-01-20 |
| Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral Neuropathy (NCT06722950) | Shandong New Time Pharmaceutical Co., LTD | 2024-12-01 |
| A Phase Ⅱ Study of Mosapride Citrate Injection in the Treatment of Postoperative Gastrointestinal Dysfunction (NCT06782594) | Shandong New Time Pharmaceutical Co., LTD | 2024-10-18 |
| A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer (NCT06755515) | Shandong New Time Pharmaceutical Co., LTD | 2024-09-26 |
| Phase III Clinical Study of Cetirizine Hydrochloride Injection in Treatment of Acute Urticaria (NCT06819774) | Shandong New Time Pharmaceutical Co., LTD | 2024-04-22 |
| Phase I Study of LNF1901 in Advanced Malignant Tumors (NCT06226363) | Shandong New Time Pharmaceutical Co., LTD | 2024-02-01 |
| Phase I Study of XZ120 in Malignant Tumors (NCT06206915) | Shandong New Time Pharmaceutical Co., LTD | 2024-02-01 |
| Bioequivalence Study of Dronedarone Hydrochloride Tablets in Healthy Subjects Under Fasting Conditions (NCT07396506) | Shandong New Time Pharmaceutical Co., LTD | 2023-06-05 |
| Bioequivalence Study of Nalfurafine Hydrochloride Orally Disintegrating Tablets on Fasting and Fed in Humans (NCT07478133) | Shandong New Time Pharmaceutical Co., LTD | 2023-05-24 |
| A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (NCT05741021) | Shandong New Time Pharmaceutical Co., LTD | 2023-03-01 |
| Bioequivalence Study of Trifluridine and Tipiracil Hydrochloride Tablets on Fasting and Fed in Humans (NCT07492173) | Shandong New Time Pharmaceutical Co., LTD | 2022-11-21 |
| the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma (NCT05408221) | Shandong New Time Pharmaceutical Co., LTD | 2022-11-11 |
| Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors (NCT05740215) | Shandong New Time Pharmaceutical Co., LTD | 2022-05-23 |
| Study of F527 in Patients With Relapsed or Refractory Lymphoma (NCT05293028) | Shandong New Time Pharmaceutical Co., LTD | 2022-05-20 |
| A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCL (NCT05178836) | Shandong New Time Pharmaceutical Co., LTD | 2022-01-01 |
| Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma (NCT04984434) | Shandong New Time Pharmaceutical Co., LTD | 2021-07-30 |
| A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma (NCT06226350) | Shandong New Time Pharmaceutical Co., LTD | 2021-03-04 |
| A Phase Ⅱ Study of F520 in Patients With Urothelial Carcinoma (NCT04636515) | Shandong New Time Pharmaceutical Co., LTD | 2021-01-01 |
| The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL). (NCT04457830) | Shandong New Time Pharmaceutical Co., LTD | 2020-11-01 |
| A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL) (NCT04457869) | Shandong New Time Pharmaceutical Co., LTD | 2020-11-01 |
| Pharmacodynamic Equivalence Study Of Orlistat Capsules 60 mg (NCT05076474) | Shandong New Time Pharmaceutical Co., LTD | 2020-10-01 |
| A Phase IV Study of Huazhi Rougan Granule in the Treatment of Non-alcoholic Simple Fatty Liver (NCT06202456) | Shandong New Time Pharmaceutical Co., LTD | 2020-05-13 |
| Phase Ⅰ Study to Evaluate the Safety and Tolerability of Using F520 (NCT03657381) | Shandong New Time Pharmaceutical Co., LTD | 2019-03-01 |